Skip to main content
Log in

Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis

  • Metastasis models
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Progression of breast cancer from an estrogen-dependent, slowly growing tumor amenable to tamoxifen treatment to an aggressive, metastatic, estrogen-independent phenotype has been mimicked by the transfection of MCF-7 breast carcinoma cells with fibroblast growth factors 1 or 4. FGF-transfected cells are aggressively tumorigenic in ovariectomized or tamoxifen-treated nude mice, conditions under which the parental cells would not produce tumors. When detection of metastasis was enhanced bylacZ transfection, the FGF-transfected MCF-7 cells were reliably metastatic to lymph nodes and frequently metastatic to lungs, in further contrast to parental cells. An antiangiogenic drug, AGM-1470, given to mice bearing tumors produced by FGF-transfected MCF-7 cells, produced a decrease in tumor size. The decreased tumor size was not as marked as that produced by treatment with pentosan polysulfate, an agent which would abrogate all autocrine or paracrine effects of the transfected FGF. Thus, increased angiogenesis may be a component of the phenotypic change produced by the FGF transfection, but other autocrine or paracrine effects may also be important.

Since a clonal FGF-4 andlacZ doubly-transfected cell line, MKL-4, progressively lost expression of the transfectedlacZ gene in individual cells, we performed successive rounds of fluorescence-activated cell sorting to select high-expressing cells. High-expressing cell populations thus obtained rapidly lost expression of ß-gal activity in continued culture. High ß-gal expressing clonal cell lines of MKL-4 cells established by either one or two rounds of low-density cloning also lostlacZ expression with continued culture. Southern analysis of DNA fromlacZ transfected cell lines showed the transfected sequences to be present and grossly intact in both high and low expressing populations. However, Northern analysis revealed that high-expressing populations of MKL-4 cells contained the mostlacZ mRNA, implying that in the unstable MKL-4 cell line, individual cells are down-regulating mRNA levels oflacZ. StablelacZ expression has been obtained in other FGF-transfected and parental MCF-7 cell lines using the same expression vector. Thus, the MKL-4 cell line is down-regulating mRNA encoding the transfected gene through a mechanism not dependent on the CMV promotor utilized in the expression vector. This evidence suggests thatlacZ expression is not a benign modification in certain cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324:1–8, 1991

    PubMed  Google Scholar 

  2. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall J, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124, 1992

    PubMed  Google Scholar 

  3. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992

    PubMed  Google Scholar 

  4. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761, 1992

    PubMed  Google Scholar 

  5. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL: Tumor angiogenesis in node-negative breast carcinoma — relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29:109–116, 1994

    PubMed  Google Scholar 

  6. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454–466, 1994

    PubMed  Google Scholar 

  7. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61, 1989

    PubMed  Google Scholar 

  8. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095–1104, 1991

    PubMed  Google Scholar 

  9. Li S, Shipley GD: Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Differ 2:195–202, 1991

    PubMed  Google Scholar 

  10. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC: Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 51:4685–4692, 1991

    PubMed  Google Scholar 

  11. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R: Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 69:772–776, 1994

    PubMed  Google Scholar 

  12. Ke Y, Fernig DG, Wilkinson MC, Winstanley JHR, Smith JA, Rudland PS, Barraclough R: The expression of basic fibroblast growth factor and its receptor in cell lines derived from normal human mammary gland and a benign mammary lesion. J Cell Sci 106:135–143, 1993

    PubMed  Google Scholar 

  13. Liscia DS, Merlo GR, Garrett C, French D, Mariani-Costantini R, Callahan R: Expression of int-2 mRNA in human tumors amplified at the int-2 locus. Oncogene 4:1219–1224, 1989

    PubMed  Google Scholar 

  14. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575–606, 1989

    PubMed  Google Scholar 

  15. Ding IYF, McLeskey SW, Chang K, Fu YM, Acol JC, Shou MT, Alitalo K, Kern FG: Expression of fibroblast growth factors (FGFs) and receptors (FGFRs) in human breast carcinomas. Proc Am Assoc Cancer Res 33:269, 1992

    Google Scholar 

  16. McLeskey SW, Ding IYF, Lippman ME, Kern FG: MDA-MB-134 breast carcinoma cells overexpress FGF receptors and are growth-inhibited by FGF ligands. Cancer Res 54:523–529, 1994

    PubMed  Google Scholar 

  17. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 53:2168–2177, 1993

    PubMed  Google Scholar 

  18. Zhang L, Kharbanda S, Chen D, Ding IYF, Kern FG: MCF-7 breast carcinoma cells transfected with an expression vector for fibroblast growth factor 1 are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Proc Am Assoc Cancer Res 35:44, 1994

    Google Scholar 

  19. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873, 1991

    PubMed  Google Scholar 

  20. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG: Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 andLacZ. Cancer Res 53: 2178–2187, 1993

    PubMed  Google Scholar 

  21. McLeskey SW, Zhang L, Kharbanda S, Gottardis M, Trock BJ, Lippman ME, Kern FG: Tumors produced by FGF-1 or FGF-4 transfected MCF-7 breast carcinoma cells are growth-inhibited by treatment with AGM 1470 or pentosan polysulfate. 10th Annual Meeting on Oncogenes, 368, 1994

  22. Partanen J, Vainikka S, Korhonen J, Armstrong E, Alitalo K: Diverse receptors for fibroblast growth factors. Prog Growth Factor Res 4:69–83, 1992

    PubMed  Google Scholar 

  23. Givol D, Yayon A: Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 6:3362–3369, 1992

    PubMed  Google Scholar 

  24. Johnson DE, Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1–41, 1993

    PubMed  Google Scholar 

  25. Basilico C, Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115–165, 1992

    PubMed  Google Scholar 

  26. Hughes SE, Hall PA: Overview of the fibroblast growth factor and receptor families: complexity, functional diversity, and implications for cardiovascular research. Card Res 27:1199–1203, 1993

    Google Scholar 

  27. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K: Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 89:8928–8932, 1992

    PubMed  Google Scholar 

  28. Miyamoto M, Naruo K-I, Seko C, Matsumoto S, Kondo T, Kurokawa T: Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property. Mol Cell Biol 13:4251–4259, 1993

    PubMed  Google Scholar 

  29. Battaglia C, Berlingieri MT, Martelli ML, Trapasso F, Delli Bovi P, Fusco A: Mitogenic and dedifferentiating effect of theK-fgf/hst oncogene on rat thyroid PC clone 3 epithelial cells. Cell Growth Differ 4: 185–192, 1993

    PubMed  Google Scholar 

  30. Levay-Young BK, Imagawa W, Wallace DR, Nandi S: Basic fibroblast growth factor stimulates the growth and inhibits casein accumulation in mouse mammary epithelial cells in vitro. Mol Cell Endocrinol 62:327–336, 1989

    PubMed  Google Scholar 

  31. Takahashi K, Suzuki K, Kawahara S, Ono T: Growth stimulation of human breast epithelial cells by basic fibroblast growth factor in serum-free medium. Int J Cancer 43:870–874, 1989

    PubMed  Google Scholar 

  32. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1:63–71, 1990

    PubMed  Google Scholar 

  33. Flamm SL, Wellstein A, Lupu R, Kern F, Lippman ME, Gelmann EP: Expression of fibroblast growth factor peptides in normal and malignant human mammary epithelial cells. Proc Am Assoc Cancer Res 30:71, 1989

    Google Scholar 

  34. Wellstein A, Zugmaier G, Califano JA III, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83:716–720, 1991

    PubMed  Google Scholar 

  35. Fantl WJ, Johnson DE, Williams LT: Signaling by receptor tyrosine kinases. Annu Rev Biochem 62:453–481, 1993

    PubMed  Google Scholar 

  36. Wang J-K, Gao G, Goldfarb M: Fibroblast growth factor receptors have different signaling and mitogenic potential. Mol Cell Biol 14:181–188, 1994

    PubMed  Google Scholar 

  37. Kan M, Huang J, Mansson P-E, Yasumitsu H, Carr B, McKeehan WL: Heparin-binding growth factor type 1 (acidic fibroblast growth factor): A potential biphasic autocrine and paracrine regulator of hepatocyte regeneration. Proc Natl Acad Sci USA 86: 7432–7436, 1989

    PubMed  Google Scholar 

  38. Pollock JD, Krempin M, Rudy B: Differential effects of NGF, FGF, EGF, cAMP, and dexamethasone on neurite outgrowth and sodium channel expression in PC-12 cells. J Neurosci 10:2626–2637, 1990

    PubMed  Google Scholar 

  39. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM: Fibroblast growth factor receptor 3: Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 269:11620–11627, 1994

    PubMed  Google Scholar 

  40. Vainikka S, Partanen J, Bellosta P, Coulier F, Basilico C, Jaye M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 11:4273–4280, 1992

    PubMed  Google Scholar 

  41. Ornitz DM, Leder P: Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem 267:16305–16311, 1992

    PubMed  Google Scholar 

  42. Burrus LW, Zuber ME, Lueddecke BA, Olwin BB: Identification of a cysteine-rich receptor for fibroblast growth factors. Mol Cell Biol 12:5600–5609, 1992

    PubMed  Google Scholar 

  43. Takahashi K, Yanoma S, Ono T: Enhancement of DNA synthesis of human epithelial carcinoma cells by acidic fibroblast growth factor. Cell Struct Funct 14:121–128, 1989

    PubMed  Google Scholar 

  44. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89–118, 1990

    PubMed  Google Scholar 

  45. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931–10934, 1992

    PubMed  Google Scholar 

  46. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070–1076, 1991

    PubMed  Google Scholar 

  47. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212–216, 1994

    PubMed  Google Scholar 

  48. Yamamoto T, Sudo K, Fujita T: Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 14:1–4, 1994

    PubMed  Google Scholar 

  49. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557, 1990

    PubMed  Google Scholar 

  50. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell linesin vitro andin vivo. Cancer Res 53: 2566–2570, 1993

    PubMed  Google Scholar 

  51. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 53:4262–4267, 1993

    PubMed  Google Scholar 

  52. Brem H, Folkman J: Analysis of experimental antiangiogenic therapy. J Ped Surg 28:445–451, 1993

    Google Scholar 

  53. Brem H, Gresser I, Grosfeld J, Folkman J: The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Ped Surg 28:1253–1257, 1993

    Google Scholar 

  54. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716–1724, 1992

    PubMed  Google Scholar 

  55. Lin W-C, Pretlow TP, Pretlow TG II, Culp LA: Development of micrometastases: earliest events detected with bacteriallacZ gene-tagged tumor cells. J Natl Cancer Inst 82:1497–1503, 1990

    PubMed  Google Scholar 

  56. Senger DR, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629–5632, 1986

    PubMed  Google Scholar 

  57. Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA: Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res 52:1018–1025, 1992

    PubMed  Google Scholar 

  58. Brünner N, Thompson EW, Spang-Thomsen M, Rygaard J, Dano K, Zwiebel JA:LacZ transduced human breast cancer xenografts as anin vivo model for the study of invasion and metastasis. Eur J Cancer 28A:1989–1995, 1992

    PubMed  Google Scholar 

  59. Krüger A, Schirrmacher V, von Hoegen P: Scattered micrometastases visualized at the single-cell level: detection and re-isolation oflacZ-labeled metastasized lymphoma cells. Int J Cancer 58:275–284, 1994

    PubMed  Google Scholar 

  60. Lin W-C, Culp LA: Altered establishment/clearance mechanisms during experimental micrometastasis with live and/or disabled bacteriallacZ-tagged tumor cells. Inv Met 12:197–209, 1992

    Google Scholar 

  61. Lampson LA, Lampson MA, Dunne AD: Exploiting thelacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of thelacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growthin situ. Cancer Res 53: 176–182, 1993

    PubMed  Google Scholar 

  62. Kurebayashi J, Kurosumi M, Dickson RB, Sonoo H: Angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) inhibits tumor angiogenesis, growth and spontaneous metastasis of MKL-4 human breast cancer cells in female athymic nude mice. Breast Cancer 1:109–115, 1994

    PubMed  Google Scholar 

  63. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG: Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5:1263–1274, 1994

    PubMed  Google Scholar 

  64. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG: MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen dependence and tamoxifen sensitivityin vivo. Breast Cancer Res Treat 34:97–117, 1995

    PubMed  Google Scholar 

  65. Sharfmann R, Axelrod J, Verma IM: Long-termin vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 88:4626–4630, 1991

    PubMed  Google Scholar 

  66. Schmidt EV, Christoph G, Zeller R, Leder P: The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol Cell Biol 10:4406–4411, 1990

    PubMed  Google Scholar 

  67. Stamminger T, Fickenscher H, Fleckenstein B: Cell type-specific induction of the major immediate early enhancer of human cytomegalovirus by cyclic AMP. J Gen Vir 71:105–113, 1990

    Google Scholar 

  68. Boshart M, Weber F, Jahn G, Korsch-Häsler K, Fleckenstein B, Schaffner W: A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521–530, 1985

    PubMed  Google Scholar 

  69. Ghazal P, Lubon H, Reynolds-Kohler C, Hennighausen L, Nelson JA: Interactions between cellular regulatory proteins and a unique sequence region in the human cytomegalovirus major immediate-early promoter. Virology 174:18–20, 1990

    PubMed  Google Scholar 

  70. Niller HH, Hennighausen L: Formation of several specific nucleoprotein complexes on the human cytomegalovirus immediate early enhancer. Nucleic Acids Res 19:3715–3721, 1991

    PubMed  Google Scholar 

  71. Lang D, Fickenscher H, Stamminger T: Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Res 20:3287–3295, 1992

    PubMed  Google Scholar 

  72. Strobl JS: A role for DNA methylation in vertebrate gene expression? Mol Endocrinol 4:181–183, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLeskey, S.W., Zhang, L., Kharbanda, S. et al. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Tr 39, 103–117 (1996). https://doi.org/10.1007/BF01806082

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806082

Key words

Navigation